LTR PHARMA LIMITED — AGM Information 2024

Nov 26, 2024

==> picture [190 x 34] intentionally omitted <==

Annual General Meeting

==> picture [960 x 213] intentionally omitted <==

A transformative year of clinical and commercial success

Australian Financial Year

Q2 2023/24

ASX listing

Clinical data presented at WMSM Dubai

Q3 2023/24 Q4 2023/24 Q1 2024/25 Q2 2024/25 Manufacturing Positive clinical Global partnership Final clinical study validation study results with Aptar Pharma results confirmed completed 470% faster TGA Special Access Strategic joint Clinical study absorption Scheme venture for recruitment demonstrated commenced telehealth platform commenced TGA Authorised Study recruitment Prescriber Scheme and dosing launched completed Q3 2023/24

AGM 2024

2

Investment Highlights

LTR Pharma positioned in a clear gap in the market

Expedited path to market

Compelling pivotal pharmacokinetic

Blockbuster Blue chip market with issues partners

Multiple upcoming milestones

AGM 2024

3

Physical causes

Psychological Impact

• ‣ Relationship problems

• ‣ Heart Health

A significant healthcare challenge affecting relationships and quality of life

• ‣ Hormone Balance

• ‣ Metabolic Health

• ‣ Medical Treatments

• ‣ Hair loss

• ‣ Mental Wellbeing

• ‣ Day to day stress

• ‣ Weight loss

• ‣ Antidepressants

==> picture [678 x 68] intentionally omitted <==

----- Start of picture text -----

Prevalence of ED with individuals with cardiovascular risk factors,
hypertension and diabetes, is reported as high as 50%
----- End of picture text -----

AGM 2024

4

Global Market Need

ED can impact physical and psychological health

==> picture [353 x 42] intentionally omitted <==

==> picture [911 x 268] intentionally omitted <==

----- Start of picture text -----

USA China
Aus
EU
60.7%
~30m ~33m ~150m
of males 45y/o+
----- End of picture text -----

AGM 2024

5

Estimated Market size

Forecast to be US$6.0B market by 2028

==> picture [816 x 311] intentionally omitted <==

----- Start of picture text -----

US$6.0B
7.0% CAGR
US$5.0B
US$4.0B $4.15B
$3.87B
$3.61B
US$3.0B $3.16B $3.38B
$2.95B
$2.76B
$2.58B
US$2.0B
US$1.0B $1.11B $1.18B $1.27B $1.36B $1.45B $1.56B $1.67B $1.79B
US$0.0B
2021 2022 2023F 2024F 2025F 2026F 2027F 2028F
US ROW
US$ billions
----- End of picture text -----

Online sales expansion Majority of ED medication is now sold through online channels

AGM 2024 6

Current treatments Gold standard are PDE5 inhibitor tablets which have several drawbacks

Phosphodiesterase-5 (PDE5) inhibitors are first-line treatments

Issues with PDE5 inhibitor tablets

Main Time before sexual Approval Generic Does not work Product Brand(s) activity for dose Date (US) availability for 30-35% of patients Sildenafil Viagra 1 hour+ 1998 Yes Long response time of 1 hour + Tadalafil Cialis 1 hour+ 2003 Yes affects spontaneity Levitra, Adverse reactions Vardenafil 1 hour+ 2003 Yes Staxyn in up to 35% of patients Avanafil Stendra 30 minutes+ 2012 No TGA early 12 mins No access

==> picture [35 x 185] intentionally omitted <==

==> picture [61 x 19] intentionally omitted <==

==> picture [154 x 16] intentionally omitted <==

==> picture [40 x 14] intentionally omitted <==

AGM 2024 7

SPONTAN[®] The Fast-Acting Solution Transforming ED treatment with speed and confidence

==> picture [26 x 26] intentionally omitted <==

Speed Matters

Peak concentration in as little as 9 mins, 470% faster than oral tablets Average onset: 12 mins vs 56 mins

Healthcare Professional Insight

Patients can respond in as little as 5 minutes, . well before peak concentration is reached[*]

*Based on healthcare professional feedback

Less is More

==> picture [14 x 14] intentionally omitted <==

==> picture [14 x 16] intentionally omitted <==

==> picture [29 x 35] intentionally omitted <==

Half the dose Similar effectiveness Better delivery consistency

Safety

Validated safety profile No severe events Clinically proven

Time to peak concentration

(minutes)

==> picture [292 x 124] intentionally omitted <==

----- Start of picture text -----

Tablets
0 20 40 60
----- End of picture text -----

AGM 2024

8

Making headlines – all eyes on LTP

LTR Pharma engaged positively with all tiers of the media in FY24, including quality, regular coverage in industry, business, health and top tier mediums.

Whilst a high volume of headlines focused on the Company’s outstanding share price growth, the story also attracted coverage in health-focused consumer mediums including Men’s Health, Body + Soul, state and national newspapers, and more. These stories were initiated in partnership with leading key opinion leader, Professor Eric Chung, and clinical practitioner and advocate, Melissa Hadley Barrett, and the Company’s management team.

==> picture [189 x 105] intentionally omitted <==

==> picture [272 x 264] intentionally omitted <==

==> picture [202 x 231] intentionally omitted <==

==> picture [202 x 229] intentionally omitted <==

AGM 2024 9

Company History

Progressed company substantially derisking the proposition

==> picture [7 x 8] intentionally omitted <==

==> picture [10 x 12] intentionally omitted <==

==> picture [10 x 10] intentionally omitted <==

==> picture [11 x 9] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [128 x 32] intentionally omitted <==

==> picture [21 x 95] intentionally omitted <==

to Establishment of the[[®]] Scientific Advisory Board in the field of Men’s Health Received early acceptance Adopted Mayne Health from IP Australia for our as a commercial manufacturing product trademark name partner to produce SPONTAN[®] to “SPONTAN[®] ” GMP standards

Acquired exclusive worldwide rights to develop, manufacture and market SPONTAN[[®]] through a licence agreement with SDS

Validated the US FDA’s 505(b)(2) regulatory pathway through an expert regulatory review

==> picture [4 x 5] intentionally omitted <==

==> picture [12 x 18] intentionally omitted <==

==> picture [12 x 16] intentionally omitted <==

==> picture [68 x 32] intentionally omitted <==

==> picture [63 x 32] intentionally omitted <==

Optimised delivery and commercial development of its nasal formulation with drug stability data from nasal spray device developer

Developed the Initial Public Offer (IPO) protocol for its Completed an oversubscribed IPO. bioequivalence Listed on the ASX on 11 December study, and gained 2023 and raised AU $7M. ethics approval

==> picture [6 x 7] intentionally omitted <==

==> picture [28 x 37] intentionally omitted <==

==> picture [16 x 20] intentionally omitted <==

==> picture [6 x 6] intentionally omitted <==

==> picture [6 x 4] intentionally omitted <==

==> picture [15 x 17] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [8 x 7] intentionally omitted <==

==> picture [6 x 6] intentionally omitted <==

==> picture [80 x 33] intentionally omitted <==

==> picture [5 x 10] intentionally omitted <==

==> picture [5 x 10] intentionally omitted <==

==> picture [7 x 7] intentionally omitted <==

Study results released Australian Early Co-development Online Platform SPONTAN[®] 's clinical study Access Scheme with Aptar Pharma (Q1 CY25) to support regulatory filings, commencement Partnership for the Increasing access enable early Australian Provision of commercialisation of through telehealth market access and SPONTAN[®] for SPONTAN in the USA preparation for licensing and unmet needs and other key partnering discussions markets

2020 Proof of Completed Conducted crucial Concept trial packaging studies derisking activities results published in for final commercial before moving into 2023 in The Journal product ahead of clinical development of Sexual Medicine bioequivalence study and commercial sales

AGM 2024

10

Board of Directors

Seasoned leadership driving innovation and growth in healthcare

LEE RODNE

(Executive Chairman)

• 25 years in healthcare and tech sectors in both public ASX and private enterprises.

• Led a healthcare spin out from ASX Fortescue Metals Group (Allied Medical, Admedus Ltd)

▲ Worked with Professor Ian Frazer on advancing therapeutic vaccines into clinical studies

▲ Track record of commercializing medical devices in Australia, North America, Europe and Asia with significant experience in Nasal Spray product sales.

MS MAJA MCGUIRE

(Independent Non-Executive Director)

• 15 years of experience providing corporate and compliance advice to ASX-listed public companies as an Australian-qualified lawyer.

• This includes working with listed companies as a non-executive director, general counsel, company secretary and in private practice.

▲ Current Non-Executive Chair of ASX listed TechGen Metals (ASX:TG1), non-executive director of Kuniko (ASX: KNI) and non-executive director of Indiana Resources Limited (ASX(IDA).

DR JULIAN CHICK

(Independent Non-Executive Director)

• 20 years experience in senior management and board positions, including in ASX-listed companies Avexa Ltd, Admedus Ltd and current Chair of Cann Group Ltd (ASX:CAN).

• Over 8 years of experience in investment banking and reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists.

11

AGM 2024

Global Team, Strategic US Presence Experienced leadership across key markets

Executive Chairman | Lee Rodne

25 years in healthcare and tech sectors in both public ASX and private enterprises.

General Manager & Business Development US | Tom Riester

25 years experience in sales and management in digital health, medical device and precision medicine.

Chief Operating Officer | Peter McLennan

17 years experience in investment banking, investor relations and operations.

Vice President – US Sales & Marketing | Mike Sweeting

30 years in the Pharmaceutical industry in US commercial sales and Market Access.

Chief Finance Officer | Jacques Shipper

14 years experience in Finance, Commercial Management and Controller roles.

Medical Liaison Officer | Chris Rosewarne

Experienced pharmaceutical and medical device industry leader with over 20 years experience.

Vice President Operations & Clinical Development | Dr Monil Shah 20 years of Pharmaceutical and biotechnology industry experience in drug development.

Vice President, Global Regulatory Affairs | Kip Vought

25 years across global markets - Senior Pharmaceutical R&D and regulatory executive.

Vice President – Commercial | Danny Zanardo

25 years commercial experience in the Australian and global healthcare sectors across pharmaceuticals and medical devices.

Chief Medical Officer | Prof Geoffrey Strange

20 years experience in Pharmaceutical and medical industries as a Senior Executive and Medical Researcher.

==> picture [285 x 46] intentionally omitted <==

AGM 2024 12

Upcoming Milestones Multiple value inflection points in the year ahead

Expanding Manufacturing product portfolio scale up

==> picture [362 x 208] intentionally omitted <==

----- Start of picture text -----

Online Regulatory
prescribing studies
& meetings
----- End of picture text -----

==> picture [179 x 208] intentionally omitted <==

----- Start of picture text -----

Potential
partnerships &
licensing
----- End of picture text -----

AGM 2024

13